35959-05-8

Usage

Uses

Used in Pharmaceutical Industry:
3-Hydroxy-11-ursen-28,13-olide is used as a potential therapeutic agent for the treatment of cancer due to its anti-tumor properties. It has been studied for its ability to inhibit the growth and progression of various types of cancer, making it a valuable target for further research and drug development.
3-Hydroxy-11-ursen-28,13-olide is also used as an anti-inflammatory agent for the treatment of inflammatory diseases. Its anti-inflammatory properties make it a promising candidate for the development of new drugs to alleviate inflammation and associated symptoms.
In addition to its direct therapeutic applications, 3-Hydroxy-11-ursen-28,13-olide can be utilized in drug delivery systems to enhance the efficacy and bioavailability of other pharmaceutical compounds. Its unique structure and biological activities can be leveraged to improve the delivery of drugs to target tissues, potentially leading to better therapeutic outcomes.
Overall, 3-Hydroxy-11-ursen-28,13-olide's diverse applications in the pharmaceutical industry highlight its potential as a valuable compound for the development of novel treatments for cancer and inflammatory diseases. Further research and development are needed to fully explore its therapeutic potential and optimize its use in various applications.

Upstream product

• 77-52-1 ursolic acid 

Downstream Products

• 35959-08-1 3β-acetoxyurs-11-en-28,13-olide 

Relevant academic research and scientific papers

Auxiliary-directed oxidation of ursolic acid by 'Ru'-porphyrins: Chemical modulation of cytotoxicity against tumor cell lines

Derivatization of ursolic acid, one of the natural ursene-type pentacyclic triterpenes, was investigated by the oxidation with dioxoruthenium(VI) tetraphenylporphyrins. Oxidation selectivity on the terpene structure was modulated by the auxiliaries introd

Biotransformation of ursolic acid by an endophytic fungus from medicinal plant Huperzia serrata

Endophytic fungi were used not only for their producing bioactive products but also for their ability to transform natural compounds. An endophytic fungus, isolated from medicinal plant Huperzia serrata, was identified as Umbelopsis isabellina based on the internal transcribed spacer of ribosomal DNA (rDNA-ITS) region. It was used to transform ursolic acid (1), a pentacyclic triterpene. Incubation of ursolic acid with U. isabellina afforded three products, 3β-hydroxy-urs-11-en-28,13-lactone (2), 3β,7β-dihydroxy-urs-11- en-28,13-lactone (3), 1β,3β-dihydroxy-urs-11-en-28,13-lactone (4). Although product 2 was a known compound, it was first obtained by microbial transformation. Products 3 and 4 were new compounds. The structural elucidation of the three compounds was achieved mainly by the 1D- and 2D-NMR, MS, IR data. The endophytic fungus U. isabellina can hydroxyate the C12-C13 double bond at position 13 of ursolic acid 1 and form a five-member lactone effectively. In the meantime, this fungus can also introduce the hydroxyl group at C-1 or C-7 of ursolic acid 1.

A new triterpenic acid from Eucalyptus robusta

A new triterpene "Robustanic acid" I has been isolated from the leaves of Eucalyptus robusta along with, ursolic acid lactone 2, sideroxylin 5, 2α 3β-dihydroxy-urs- 12-ene-28-oic acid 6. ursolic acid 7, β-sitosterol-β-D-glucoside 8 and gallic acid 9. On the other hand, stem results in the isolation and characterization of β-sitosterol 10 and an isomeric mixture of oleanolic acid 11 and ursolic acid 7. The structure of new triterpenic acid has been deduced as 3β-hydroxy, 11α-methoxy-urs-12-ene-28-oic acid on the basis of spectroscopic data and chemical correlation with compounds of established structure. Presence of compounds 6, 7, 8, 9 and 11 in E. robusta is being reported for the first time.